相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic intervention for Alzheimer's disease with γγ-secretase inhibitors: still a viable option?
Bruno P. Imbimbo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
G. K. Wilcock et al.
LANCET NEUROLOGY (2011)
Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
Taro Goto et al.
Alzheimers & Dementia (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease Rationale and Current Evidence
Richard Dodel et al.
DRUGS (2010)
Bapineuzumab
Geoffrey A. Kerchner et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
MECHANISMS OF DISEASE Alzheimer's Disease
Henry W. Querfurth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Recent developments in Alzheimer's disease therapeutics
Michael S. Rafii et al.
BMC MEDICINE (2009)
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
John Hardy
JOURNAL OF NEUROCHEMISTRY (2009)
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Kaoru Yamada et al.
JOURNAL OF NEUROSCIENCE (2009)
Factors associated with resistance to dementia despite high Alzheimer disease pathology
D. Erten-Lyons et al.
NEUROLOGY (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Eric R. Siemers et al.
Alzheimers & Dementia (2008)
Alzheimer disease pathology as a host response
Rudy J. Castellani et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Rachelle S. Doody et al.
LANCET (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Gordon K. Wilcock et al.
LANCET NEUROLOGY (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
[Anonymous]
LANCET NEUROLOGY (2008)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Vaccination strategies for Alzheimer's disease - A new hope?
Adele Woodhouse et al.
DRUGS & AGING (2007)
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody
KR Bales et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
H Kaduszkiewicz et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration
DM Wilcock et al.
NEUROBIOLOGY OF DISEASE (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Intracerebroventricular passive immunization with anti-Aβ antibody in Tg2576
NB Chauhan et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart et al.
NATURE NEUROSCIENCE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial
PN Tariot et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
